Weaver C. Barksdale & Associates’s Novartis NVS Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-19,351	Closed	-$1.29M	–	525
2017 Q1	$1.29M	Buy	19,351 +5,226	+37%	+$348K	1.52%	37
2016 Q4	$922K	Buy	14,125 +4,868	+53%	+$316K	1.49%	39
2016 Q3	$655K	Buy	9,257 +1,039	+13%	+$75.7K	1.1%	55
2016 Q2	$608K	Hold	8,218	–	–	1.06%	55
2016 Q1	$533K	Sell	8,218 -103	-1%	-$7.01K	0.4%	85
2015 Q4	$642K	Hold	8,321	–	–	0.5%	77
2015 Q3	$685K	Hold	8,321	–	–	0.55%	69
2015 Q2	$733K	Hold	8,321	–	–	0.54%	73
2015 Q1	$735K	Sell	8,321 -204	-2%	-$18.1K	0.55%	69
2014 Q4	$708K	Sell	8,525 -391	-4%	-$32.4K	0.57%	76
2014 Q3	$752K	Hold	8,916	–	–	0.62%	57
2014 Q2	$723K	Buy	8,916 +3,125	+54%	+$246K	0.58%	65
2014 Q1	$441K	Sell	5,791 -318	-5%	-$23.2K	0.37%	80
2013 Q4	$440K	Sell	6,109 -148	-2%	-$10.3K	0.37%	78
2013 Q3	$430K	Buy	6,257 +4,715	+306%	+$312K	0.39%	68
2013 Q2	$98K	Buy	+1,542	New	+$100K	0.1%	110

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Weaver C. Barksdale & Associates's NVS Position: Q2 2017 in Review

Weaver C. Barksdale & Associates sold out of Novartis (NVS) in Q2 2017, closing a stake of 19,351 shares — an estimated $1.29M sold.

Weaver C. Barksdale & Associates first reported a position in NVS in Q2 2013 and held it in 16 quarters. The position peaked at $1.29M in Q1 2017. 921 funds tracked by Wall St. Rank hold NVS as of Q2 2017.

Weaver C. Barksdale & Associates reported no remaining Novartis position as of Q2 2017 after selling out during the quarter.
Weaver C. Barksdale & Associates sold 19,351 Novartis shares in Q2 2017, an estimated $1.29M.
Weaver C. Barksdale & Associates first reported a position in Novartis in Q2 2013 and held it in 16 quarters.
Weaver C. Barksdale & Associates's Novartis position peaked at $1.29M in Q1 2017.
921 funds tracked by Wall St. Rank held Novartis as of Q2 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2017, filed 13 Jul 2017.